• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates

    7/17/24 9:39:19 AM ET
    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email

    U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling around 300 points on Wednesday.

    Following the market opening Wednesday, the Dow traded down 0.10% to 40,914.80 while the NASDAQ fell 1.63% to 18,208.05. The S&P 500 also fell, dropping, 0.98% to 5,611.77                                 .

    Check This Out: Amazon To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday

    Leading and Lagging Sectors

    Energy shares jumped by 0.5% on Wednesday.

    In trading on Wednesday, information technology shares fell by 2.3%.

    Top Headline

    Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday.

    The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion.

    Johnson & Johnson raised fiscal year 2024 operational sales guidance to $89.2 billion-$89.6 billion versus prior guidance of $88.7 billion-$89.1 billion.

    Equities Trading UP
                           

    • Aditxt, Inc. (NASDAQ:ADTX) shares shot up 67% to $2.66. Aditxt and Evofem amended merger agreement.
    • Shares of Locafy Limited (NASDAQ:LCFY) got a boost, surging 41% to $7.69.
    • Shimmick Corporation (NASDAQ:SHIM) shares were also up, gaining 36% to $2.74 after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project.

    Equities Trading DOWN

    • ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares dropped 57% to $0.4813 after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation.
    • Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) were down 27% to $9.91 after announcing changes in executive leadership. The company named Rick Barry as Executive Chairman and Principal Executive Office and said Remi Barbier resigned as President, CEO, and Board Member.
    • NaaS Technology Inc. (NASDAQ:NAAS) was down, falling 14% to $4.0097.

    Also Check This Out: Alphabet, CrowdStrike And 2 Other Stocks Insiders Are Selling

    Commodities

    In commodity news, oil traded up 0.6% to $81.23 while gold traded up 0.2% at $2,473.50.

    Silver traded down 1% to $31.155 on Wednesday, while copper fell 0.5% to $4.4285.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX fell 0.6% and France's CAC 40 fell 0.5%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.1%.

    Annual inflation rate in the Eurozone eased to 2.5% in June from 2.6% in May. French current account deficit shrank to EUR 3.1 billion in May versus a revised EUR 3.5 billion in the prior month.

    U.K. producer prices increased 1.4% year-over-year in June following a 1.7% rise in the prior month, while annual inflation rate came in steady at 2% in June.

    Asia Pacific Markets

    Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 0.43%, Hong Kong's Hang Seng Index gaining 0.06% and China's Shanghai Composite Index falling 0.45%.

    Singapore’s non-oil domestic exports fell by 8.7% year-over-year in June following a revised 0.7% decline in May.

    Economics

    • U.S. mortgage applications climbed by 3.9% during the third week of July.
    • U.S. housing starts increased by 3% from the prior month to an annualized rate of 1,314,000 in June compared to a revised 4.6% fall a month ago.
    • Building permits in the U.S. climbed by 3.4% to an annual rate of 1.446 million in June.

    Now Read This: How To Earn $500 A Month From Domino’s Stock Ahead Of Q2 Earnings Report

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $ASLN
    $JNJ
    $LCFY

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Shimmick Corporation
    $SHIM
    1/5/2026$6.00Hold → Buy
    Craig Hallum
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

    OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse eventsi Additional data presented further reinforces the favorable and consistent safety and efficiency profile of the VARIPULSE platformii,iii,iv,v Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib), during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases w

    2/6/26 7:00:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

    Johnson & Johnson (NYSE:JNJ) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026. Management will participate in a Fireside Chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260202922675/en/ Media contact: [email protected] Investor contact: [email protected]

    2/2/26 4:34:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

    Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care    Approval marks the twelfth indication for DARZALEX FASPRO® and fifth in the newly diagnosed setting, underscoring its role as foundational therapy for both newly diagnosed and relapsed/refractory multiple myeloma patients HORSHAM, Pa., Jan. 27, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with

    1/27/26 3:49:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Forminard Elizabeth exercised 8,921 shares at a strike of $129.51 and covered exercise/tax liability with 6,226 shares, increasing direct ownership by 21% to 15,548 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/6/26 5:46:50 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson Paula A decreased direct ownership by 11% to 89 units (SEC Form 5)

    5 - JOHNSON & JOHNSON (0000200406) (Issuer)

    1/28/26 6:29:28 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman of the Board Duato Joaquin sold $22,122,893 worth of shares (100,000 units at $221.23) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    1/28/26 6:07:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shimmick Corp. upgraded by Craig Hallum with a new price target

    Craig Hallum upgraded Shimmick Corp. from Hold to Buy and set a new price target of $6.00

    1/5/26 8:21:55 AM ET
    $SHIM
    Military/Government/Technical
    Industrials

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    SEC Filings

    View All

    SEC Form 6-K filed by NaaS Technology Inc.

    6-K - NaaS Technology Inc. (0001712178) (Filer)

    2/5/26 4:30:05 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Johnson & Johnson

    SCHEDULE 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/5/26 12:23:53 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Aditxt Inc.

    SCHEDULE 13G - Aditxt, Inc. (0001726711) (Subject)

    1/30/26 8:02:33 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Chief Financial Officer Yoder Todd Wilbur bought $5,600 worth of shares (2,000 units at $2.80) (SEC Form 4)

    4/A - Shimmick Corp (0001887944) (Issuer)

    12/2/25 4:18:47 PM ET
    $SHIM
    Military/Government/Technical
    Industrials

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

    AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,

    10/22/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson reports Q4 and Full-Year 2025 results

    2025 Fourth-Quarter reported sales growth of 9.1% to $24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of $2.10 and adjusted EPS of $2.46, both include $(0.10) due to the acquisition of Halda Therapeutics 2025 Full-Year reported sales growth of 6.0% to $94.2 Billion with operational growth of 5.3%* and adjusted operational growth of 4.2%*; 2025 Full-Year earnings per share (EPS) of $11.03 and adjusted EPS of $10.79, both include $(0.10) due to the acquisition of Halda Therapeutics Significant innovation including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for

    1/21/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company's common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely p

    1/2/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay

    12/15/25 4:27:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 9:58:25 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 5:31:20 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care